Citi Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Goldman Sachs Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
October 10, 2024 5:36 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $370.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)
The analyst comments "We attended ALNY's TTR day, where management discussed the launch strategy for Amvuttra in ATTR-cardiomyopathy (CM; supplemental NDA submitted, and we anticipate approval in 2Q25), notably: (1) key patient segments, where ALNY plans to first establish Amvuttra as the 1L... More
BofA Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
October 10, 2024 5:30 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $307.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "ALNY highlighted the commercial strategy for the Amvuttra launch in ATTR-CM at their TTR Day. Mgmt emphasized the launch strategy will... More
Alnylam Pharma (ALNY) Submits sNDA to FDA for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
October 9, 2024 7:03 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with... More
